Tags

Type your tag names separated by a space and hit enter

Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Breast Cancer Res Treat 2016; 157(3):545-54BC

Abstract

Triple negative (TN, tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2)) and HER2-overexpressing (H2E, ER-/HER2+) tumors are two particularly aggressive subtypes of breast cancer. There is a lack of knowledge regarding the etiologies of these cancers and in particular how anthropometric factors are related to risk. We conducted a population-based case-case study consisting of 2659 women aged 20-69 years diagnosed with invasive breast cancer from 2004 to 2012. Four case groups defined based on joint ER/PR/HER2 status were included: TN, H2E, luminal A (ER+/HER2-), and luminal B (ER+/HER2+). Polytomous logistic regression was used to estimate odds ratios (ORs) and associated 95 % confidence intervals (CIs) where luminal A patients served as the reference group. Obese premenopausal women [body mass index (BMI) ≥30 kg/m(2)] had an 82 % (95 % CI 1.32-2.51) increased risk of TN breast cancer compared to women whose BMI <25 kg/m(2), and those in the highest weight quartile (quartiles were categorized based on the distribution among luminal A patients) had a 79 % (95 % CI 1.23-2.64) increased risk of TN disease compared to those in the lowest quartile. Among postmenopausal women obesity was associated with reduced risks of both TN (OR = 0.74, 95 % CI 0.54-1.00) and H2E (OR = 0.47, 95 % CI 0.32-0.69) cancers. Our results suggest obesity has divergent impacts on risk of aggressive subtypes of breast cancer in premenopausal versus postmenopausal women, which may contribute to the higher incidence rates of TN cancers observed among younger African American and Hispanic women.

Authors+Show Affiliations

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop M4-C308, P.O. Box 19024, Seattle, WA, 98109, USA. clu@fredhutch.org.Department of Internal Medicine, University of New Mexico and the University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop M4-C308, P.O. Box 19024, Seattle, WA, 98109, USA.Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop M4-C308, P.O. Box 19024, Seattle, WA, 98109, USA. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.Department of Internal Medicine, University of New Mexico and the University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.Department of Internal Medicine, University of New Mexico and the University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop M4-C308, P.O. Box 19024, Seattle, WA, 98109, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

27220749

Citation

Chen, Lu, et al. "Body Mass Index and Risk of Luminal, HER2-overexpressing, and Triple Negative Breast Cancer." Breast Cancer Research and Treatment, vol. 157, no. 3, 2016, pp. 545-54.
Chen L, Cook LS, Tang MT, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016;157(3):545-54.
Chen, L., Cook, L. S., Tang, M. T., Porter, P. L., Hill, D. A., Wiggins, C. L., & Li, C. I. (2016). Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Research and Treatment, 157(3), pp. 545-54. doi:10.1007/s10549-016-3825-9.
Chen L, et al. Body Mass Index and Risk of Luminal, HER2-overexpressing, and Triple Negative Breast Cancer. Breast Cancer Res Treat. 2016;157(3):545-54. PubMed PMID: 27220749.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. AU - Chen,Lu, AU - Cook,Linda S, AU - Tang,Mei-Tzu C, AU - Porter,Peggy L, AU - Hill,Deirdre A, AU - Wiggins,Charles L, AU - Li,Christopher I, Y1 - 2016/05/24/ PY - 2016/03/03/received PY - 2016/05/05/accepted PY - 2016/5/26/entrez PY - 2016/5/26/pubmed PY - 2017/11/29/medline KW - BMI KW - Breast cancer KW - Obesity KW - Triple negative SP - 545 EP - 54 JF - Breast cancer research and treatment JO - Breast Cancer Res. Treat. VL - 157 IS - 3 N2 - Triple negative (TN, tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2)) and HER2-overexpressing (H2E, ER-/HER2+) tumors are two particularly aggressive subtypes of breast cancer. There is a lack of knowledge regarding the etiologies of these cancers and in particular how anthropometric factors are related to risk. We conducted a population-based case-case study consisting of 2659 women aged 20-69 years diagnosed with invasive breast cancer from 2004 to 2012. Four case groups defined based on joint ER/PR/HER2 status were included: TN, H2E, luminal A (ER+/HER2-), and luminal B (ER+/HER2+). Polytomous logistic regression was used to estimate odds ratios (ORs) and associated 95 % confidence intervals (CIs) where luminal A patients served as the reference group. Obese premenopausal women [body mass index (BMI) ≥30 kg/m(2)] had an 82 % (95 % CI 1.32-2.51) increased risk of TN breast cancer compared to women whose BMI <25 kg/m(2), and those in the highest weight quartile (quartiles were categorized based on the distribution among luminal A patients) had a 79 % (95 % CI 1.23-2.64) increased risk of TN disease compared to those in the lowest quartile. Among postmenopausal women obesity was associated with reduced risks of both TN (OR = 0.74, 95 % CI 0.54-1.00) and H2E (OR = 0.47, 95 % CI 0.32-0.69) cancers. Our results suggest obesity has divergent impacts on risk of aggressive subtypes of breast cancer in premenopausal versus postmenopausal women, which may contribute to the higher incidence rates of TN cancers observed among younger African American and Hispanic women. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/27220749/Body_mass_index_and_risk_of_luminal_HER2_overexpressing_and_triple_negative_breast_cancer_ L2 - https://doi.org/10.1007/s10549-016-3825-9 DB - PRIME DP - Unbound Medicine ER -